The roles of pre-season immunity, age, viral shedding, and community exposures in shaping influenza household transmission dynamics

Molly K Sauter[1,2], Jackie Kleynhans[3,4], Jocelyn Moyes[3,4], Meredith L McMorrow[5,6], Florette K Treurnicht[3], Orienka Hellferscee[3,7], Anne von Gottberg[3,7], Nicole Wolter[3,7], Amelia Buys[3], Lorens Maake[3], Neil A Martinson[8,9,10], Kathleen Kahn[11], Limakatso Lebina[8], Katlego Motlhaoleng[8], Floidy Wafawanaka[11], Francesc Xavier Gómez-Olivé[11], Stefano Tempia[,4,5,6,12], Bryan Grenfell[2], Cecile Viboud[1], Kaiyuan Sun[1¶*], Cheryl Cohen[3,4¶*]

[1] Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of America

[2] Department of Ecology and Evolutionary Biology, Princeton University, Princeton, New Jersey, United States of America

[3] Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa

[4] School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

[5] Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

[6] Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa

[7] School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

[8] Perinatal HIV Research Unit, MRC Soweto Matlosana Collaborating Centre for HIV/AIDS and TB, University of the Witwatersrand, South Africa

[9] DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, University of the Witwatersrand, Johannesburg, South Africa

[10] Johns Hopkins University Center for TB Research, Baltimore, Maryland, United States of America

[11] MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

[12] MassGenics, Duluth, Georgia, USA

*Corresponding authors. Email: kaiyuan.sun@nih.gov (KS); cherylc@nicd.ac.za (CC)

¶These authors contributed equally

Abstract

Our understanding of influenza transmission remains imperfect due to the high prevalence of asymptomatic infections that often go undetected. To address this challenge, we leveraged uniquely resolved data from a household cohort study spanning three consecutive years in rural and urban South Africa. The study incorporated pre-season serum collection and twice-weekly virological testing during the influenza season, regardless of symptom presence. We developed a subtype/lineage-specific influenza household transmission model that accounts for time-resolved viral shedding across the full clinical spectrum of infections, allowing us to disentangle the role of household and community exposures, pre-season immunity, and age on transmission. Our analysis revealed that viral shedding intensity, as measured by the cycle threshold (Ct) values of infected household members, significantly correlated with the risk of transmission for all four influenza subtypes/lineages. After adjusting for viral shedding, pre-season hemagglutination inhibition (HAI) titers greater than 1:40 were associated with a significantly lower risk of infection acquisition for A(H1N1)pdm09, A(H3N2), and B/Victoria, but not for B/Yamagata. Notably, children exhibited higher susceptibility and longer viral shedding durations compared to adults across all subtypes/lineages, even after adjusting for pre-season HAI titers. While our findings support that HAI titers correlate with protection, the strong residual effects of age on susceptibility and viral shedding may reflect the accumulation of additional immune responses shaped by repeated exposures over time. Our study underscores the need to explore immune mechanisms beyond HAI titers that modulate influenza susceptibility and transmission.

Introduction

Refining our understanding of influenza transmission is essential for identifying key risk factors for infection, characterizing protective immunity, and informing prevention strategies to reduce disease burden. Human challenge studies have provided valuable insights into the role of prior immunity and exposure dose on infection risk. Yet, these studies involve healthy volunteers in controlled laboratory settings and may not adequately represent the diverse populations and real-world contexts in which influenza spreads [1,2]. In parallel, studying influenza transmission in real-world settings is challenging due to the acute nature of infection, with viral shedding typically lasting only 3 to 6 days, and a high prevalence of asymptomatic infections [1,3–5]. Consequently, the two observational study designs traditionally used to assess influenza transmission and protective immunity – household cohort studies and case-ascertained household transmission studies – often encounter difficulties in tracking infections and capturing transmission dynamics [6]. Overcoming these challenges through improved study designs remains a priority to enhance our understanding of influenza transmission and inform more effective intervention strategies.

The Prospective Household cohort study of Influenza, Respiratory Syncytial virus, and other respiratory pathogens community burden and Transmission dynamics in South Africa (PHIRST) aims to address these challenges by introducing the collection of pre-season serum samples followed by twice-weekly respiratory virological testing regardless of symptom presence throughout the influenza season [7]. This unique design leverages the distinct strengths of traditional observational studies while overcoming key limitations. Prior household cohort studies have sampled based on symptomatic illness and/or inferred infections from paired sera. Although the paired sera approach can detect asymptomatic and subclinical infections, its

sensitivity and specificity are limited, and it lacks precision in determining the timing of

infection [6,8–10]. Case-ascertained household transmission studies have relied on clinical visits of

symptomatically infected individuals to enroll index cases and their households, neglecting

transmission events initiated by asymptomatic individuals and those who do not seek care [5,6,11,12].

In contrast, systematic and asymptomatic testing in the PHIRST cohort allows for the precise

identification of influenza infections and household index cases across the clinical spectrum of

disease, eliminating the bias towards symptomatic transmission. Further, the PHIRST cohort

enables the assessment of the relationship between pre-existing immunity and the risk of

infection [6,8–10], along with direct observation of transmission events through repeated virological

testing at short time intervals [5,6,11]. Specifically, these data provide the means to reconstruct viral

shedding kinetics for each influenza-infected participant during the study period, which permits

the characterization of time-varying influenza exposure risk for susceptible household members.

In this study, leveraging the PHIRST study's unique design and comprehensive data

collection in a high transmission setting, we developed a highly detailed household transmission

model to understand how influenza virus exposure intensity, age, and serum HAI titers influence

the risk of infection acquisition. We are particularly interested in quantifying the role of prior

immunity while accounting for influenza virus exposure, and vice versa. We also provide

valuable insights into influenza virus transmission from low- and middle-income countries,

where the burden of influenza is heightened by low vaccination rates, population demographics,

and a high prevalence of comorbidities [13–16].

Methods

Study design

The PHIRST study enrolled participants from two study sites in rural and urban

communities of South Africa[7]. The rural site was in the Agincourt sub-district of the

Mpumalanga Province Demographic Surveillance Site, an established health and socio-

demographic surveillance site (HDSS) since 1992. The urban study site was the Jouberton

suburb of Klerksdorp in the North West Province. New cohorts of households were enrolled each

year from 2016 to 2018 prior to the start of the winter influenza season, which typically runs

from May to September in South Africa's temperate climate. In Agincourt, households were

randomly selected from the HDSS database and in Klerksdorp, selection was based on proximity

to randomly generated global positioning system (GPS) coordinates. Successful enrollment

required that the household had more than 2 members and that at least 80% of the members

provided written consent, or written assent and consent from a parental guardian for household

members <17 years old. Each year we enrolled an average of 55 new households, or 281

individuals, per study site. A total of 327 households and 1684 individuals were successfully

enrolled and completed follow-up surveys and samples over the duration of the three-year study.

Upon enrollment we collected demographic, household, and baseline health data,

including an offer of HIV testing to all participants who did not have a known HIV status and

were over 10 years old; children were tested at birth and, when negative, were assumed to be

negative through age 10. Blood serum samples were collected at least once prior to each

influenza season. After enrollment the participants entered an intensive follow up period for six

months in 2016, and 10 months in 2017 and 2018, spanning the entirety of the influenza season.

Trained investigators visited each household twice weekly to collect nasopharyngeal swabs

regardless of the presence of symptoms or health-seeking behavior.

Laboratory Testing

Influenza antibody titers were measured with HAI assays against strains circulating during the study period: A/South Africa/2517/2016 (A(H1N1)pdm09), A/Singapore/INFIMH-16-0019/2016 (A(H3N2)), B/South Africa/R3037/2016 (B/Victoria), and B/South Africa/R05631/2017 (B/Yamagata). The same viruses were used for all three study years. Nasopharyngeal swabs were tested for influenza with rRT-PCR using the FTD Flu/RSV detection assay (Fast Track Diagnostics, Luxembourg) [7,17]. Positive samples were further analyzed to determine the influenza subtype or lineage with the US CDC influenza A subtyping kit or the CDC influenza B Yamagata and Victoria lineages typing kit (available through International Reagent Resource Program; http://www.internationalreagentresource.org) [7,17]. The cohort design, enrollment, testing, and laboratory protocols have all been described in detail in previous publications [7].

Analytical Approach

To build a household transmission model that captures the daily risk of influenza virus infection based on the shedding dynamics of infected household members, we first estimated the viral shedding kinetics of each observed infection episode. Episodes were defined by clustering influenza-positive samples (rRT-PCR cycle threshold (Ct) value <37) that were less than 14 days apart and of the same subtype [3]. Some samples tested positive for an influenza type but did not reach the threshold for positivity on the corresponding subtype or lineage assay. If non-subtyped samples were temporally clustered with samples that could be subtyped, they were assumed to be a part of the same infection episode. We observed limited instances of co-circulation of influenza virus subtypes causing 25 instances of coinfection (4% of all observed infections) which were

excluded from our analysis, as it is challenging to attribute the Ct value accurately to a single

subtype in the presence of co-infection.

The rRT-PCR Ct value has been shown to provide a quantitative proxy (though not a

direct measure) of a sample's viral load and has been used in previous studies of influenza

transmission [1,5,18]. Based on previous work, we assumed an exponential increase in viral load

during the proliferation stage, defined as the period from the onset of shedding to the peak viral

load, followed by an exponential decrease during the clearance stage, defined as the period from

the peak viral load to the end of shedding [19,20]. This translates to a linear decrease in Ct value

from the threshold value of 37 to a minimum Ct value (i.e., proxy peak viral load), followed by a

linear increase in Ct from the minimum to detection threshold. Hence, shedding kinetics can be

modeled as a piecewise linear function and fitted to serial Ct values of each infection episode,

where Ct values are based on the multiplex FTD Flu/RSV detection assay. To calibrate the

model, we implemented a Bayesian hierarchical framework using the Hamiltonian Monte Carlo

(HMC) algorithm to generate posterior draws for parameter inference. Each draw estimates the

value and timing of the minimum Ct (a proxy for peak viral load), as well as the durations of the

proliferation and clearance phases, both at the population mean for each subtype or lineage and

at the individual (per-infection episode) level. From the individual model estimates and our

knowledge of the timing of the infection episode within the season, we determined start and end

dates of each infection episode to establish a timeline of infection within the household and study

site. The onset of infection was set as one day prior to the first day of shedding based on kinetics

observed in challenge studies [1,2] (for model equations and details see Supplementary Text). In all

following regression analysis, to account for uncertainty in the shedding estimates due to

potential censoring or missing observations, we resampled from the posterior; each regression

was run 100 times, drawing one random posterior estimate per individual from the shedding

model outputs, and the resulting regression estimates were pooled to obtain the final reported

values.

Next, we explored individual factors that are predictive of viral shedding duration and

peak viral load (estimated minimum Ct). We used a mixed effects multiple linear regression fit

separately to each subtype/lineage and viral kinetics characteristic (total shedding duration and

peak viral load) with fixed effects covariates including age, sex, and HIV infection status and

year as a random effect; as B/Yamagata only circulated in 2017, a multiple linear regression with

no random effect was used. HIV status was included as a covariate given the high prevalence of

participants living with HIV (PLWH) in the study population and its potential relevance to

influenza transmission dynamics. HAI antibody titers are commonly used serologic markers of

protective humoral immunity to influenza infection with a titer cutoff of 1:40 described to

provide 50% protection against the infection [21–23]. Thus, we also included the participant's pre-

season HAI titer grouped as either above or equal to 1:40 or less than 1:40 as an indicator of pre-

season immunity. For the majority of individuals, we used the geometric means of two draws

from a serological sample taken closest to the start of the influenza season, between March and

May; however, for the 87 (5.7%) individuals that did not have a blood draw in this time period,

we interpolated their titer measurement based on the initial serological measurement taken

between November and February. To do so, for individuals that had both a draw in November-

February and March-May, we linearly regressed the March-May titer draw against the

November-February draw as well as a selection of age, sex, and HIV status of the individual that

created the best fit transmission model for each subtype (for model testing see Supplementary

Tables 2 and 3). We then used this regression to interpolate the March-May draw based on the

November-February draw for those missing this second draw. The shedding regression models

were fit separately to each influenza subtype/lineage.

To assess predictors of influenza virus infection risk, we employed piecewise exponential

survival models with time-varying covariates. These models integrated daily estimates of viral

shedding intensity, community influenza prevalence, and other relevant covariates[20,24,25]. The

piecewise exponential model was estimated using Poisson regression, with each individual's

daily infection status as the binary outcome and corresponding daily covariates. At the start of

the season, all individuals were considered susceptible and were then excluded from the risk set

following the onset of infection with a specific subtype or lineage. Although individuals were no

longer deemed susceptible after infection onset, their infection status and shedding intensity

continued to contribute to the transmission risk for other household members. A time-varying

covariate representing the household force of infection (FOI) was calculated by summing the

estimated daily shedding intensities of all influenza-infected individuals within the household.

We also included a community FOI term, derived from the prevalence of each influenza subtype

within the cohort at the corresponding study site and year. This was measured as the daily

number of PCR-positive individuals divided by the total population at the site (see

Supplementary Fig 10). Data for A(H1N1)pdm09 and B/Victoria included observations from

both 2016 and 2018, while observations for A(H3N2) and B/Yamagata were restricted to 2017.

Additional individual-level covariates included pre-season HAI titer, age, sex, HIV status, and

household size. Further methodological details are provided in the Supplementary Text.

Results

Cohort Description

The PHIRST participants were young (56% of the individuals were <18 years old) and

resided in large households (40% of households had over 5 members). HIV prevalence was high

with 16% of participants living with HIV (PLWH) and 19% of PLWH having a CD4 count less

than 200 (an indication of immune suppression). No individuals included in this analysis had

received an influenza vaccine for the then-current year. Table 1 lists individual and household

characteristics for individuals that completed the follow-up period, provided all necessary

samples, and had pre-season titer samples analyzed (see [7] for a complete cohort profile).   Over

the three years of the study, there were 1258 influenza-positive specimens, comprising around

1% of all the specimens collected. Among the 1518 individuals included in the analysis, 513

(34%) experienced at least one influenza virus infection episode within the year of the

individual's study enrollment. All four known circulating subtypes/lineages of seasonal influenza

were captured over the course of the three-year study. In 2016, the shortest data collection

period, the predominant subtypes/lineages were A(H1N1)pdm09 and B/Victoria, though there

was some co-circulation of A(H3N2). Conversely, A(H3N2) and B/Yamagata led circulation in

2017. A(H1N1)pdm09 and B/Victoria returned to predominance in 2018 (for sampling results

across all years, see Supplementary Figs 4-6).

The highest pre-season HAI titers were typically found in individuals between the ages of

10 and 20 years for all the four observed subtypes/lineages (Fig 1). The steepest age gradient in

the titers was found between the ages of 0 and 10 years for both influenza A subtypes, while the

increase was less pronounced for B/Victoria and spans a broader age range of 0 to 25 years for

B/Yamagata. After a peak in individuals in early teenage or adulthood, the titers for all subtypes

demonstrated a decline across ages followed by a plateau at older ages around a titer measure of

20-30. In contrast, titer variation started at a high level in early childhood and increased

slightly—except for B/Victoria, which declined monotonically, before gradually decreasing with age. This pattern reflects the stochastic nature of infection acquisition and immune boosting in early life, which becomes averaged out as individuals accumulate more exposures over time, as well as intrinsic individual heterogeneity in antibody responses to influenza viruses.

Viral RNA shedding trajectories were estimated for 623 infection episodes, of which 133 (21%) were A(H1N1)pdm09, 195 (31%) were A(H3N2), 220 (35%) were B/Victoria, and 75 (12%) were B/Yamagata (Table 1). Fig 2 summarizes the viral shedding kinetics estimates for each subtype/lineage. The median proliferation duration was similar across subtype (Fig 2B; A(H1N1)pdm09 2.20 days, IQR: 1.98-2.60; A(H3N2) 1.87 days, IQR: 1.62-2.28; B/Victoria 1.78 days, IQR: 1.56-2.16; B/Yamagata 1.86 days, IQR: 1.75-2.26). The median clearance duration was consistently longer than the proliferation duration for all subtypes, and slightly, though not significantly longer, for both type B lineages compared to type A subtypes (Fig 2C; A(H1N1)pdm09 2.52 days, IQR: 1.95-4.47; A(H3N2) 2.57 days, IQR: 2.07-4.92; B/Victoria 3.04 days, IQR: 2.30-5.86; B/Yamagata 3.26 days, IQR: 2.51-5.97). Accordingly, the total durations were similar across subtypes/lineages (Fig 2D; A(H1N1)pdm09 4.7 days, IQR: 4.0-75; A(H3N2) 4.6 days, IQR: 3.8-7.7; B/Victoria 5.2 days, IQR: 4.0-8.4; B/Yamagata 5.3 days, IQR: 4.4-8.4). The coefficients of variation were higher for the clearance duration than proliferation duration, significantly so for all but A(H3N2) by asymptomatic testing for equality of coefficients of variation (p-value < 0.05) [26]. (Supplementary Table 1). The median estimated peak viral load as proxied by minimum Ct for the episode ranged from 19.8 Ct for A(H3N2) to 22.0 Ct for A(H1N1)pdm09 (Fig 2E; A(H1N1)pdm09 22.0 Ct, IQR: 19.8-23.5; A(H3N2) 19.8 Ct, IQR: 18.4-20.2; B/Victoria 20.5 Ct, 19.3-21.3; B/Yamagata 19.9 Ct, IQR: 17.1-21.1).

Age and pre-season HAI titers association with the shedding kinetics of seasonal influenza

Fig 3 shows predictors of the total duration and the peak viral load (minimum Ct) of viral RNA shedding by influenza subtype/lineage. For A(H1N1)pdm09 infections, higher pre-season HAI titers correlated with shorter durations of shedding, with a 2.3-day reduction in duration time for those with a titer of at least 40 compared to those with lower titers [95% confidence interval (CI): -3.90 - -0.41 days]. This was not seen for other subtypes/lineages. Younger individuals tended to shed for longer, even after adjusting for HAI titers. In particular, children <5 years old exhibited a 3-5 day longer shedding duration for all subtypes/lineages apart from B/Yamagata compared to persons >40 years old (A(H1N1)pdm09 3.33 days, 95% CI: 0.87-5.79; A(H3N2) 4.16 days, 95% CI: 1.72-6.61; B/Victoria 4.46 days, 95% CI: 1.24-7.69). Children aged 5-11 years also demonstrated longer durations for infections of A(H1N1)pdm09 [2.67 days, 95% CI: 0.21-5.13] and A(H3N2) [2.64 days, 95% CI: 0.65-4.64]. HIV status, even among the immunocompromised, was not significantly associated with the total duration of shedding for any of the influenza subtypes. Regarding peak viral load, no significant association was found between any of the included covariates and viral load reduction for any subtype or lineage (Fig 3, bottom panel).

Household and community influenza exposures, pre-season HAI titers, and age jointly shape the risk of influenza acquisition

Next, we used the shedding data to inform a daily transmission model accounting for time-varying influenza exposure in the household. We also considered time-varying infection

risk from the community, and demographic and immunological characteristics of household

members, using a multivariable logistic regression framework (see Fig 4 and methods for details

on the approach, and Fig 5 for results). We find a strong effect of the household force of infection

(FOI, proxied by viral shedding) on risk of infection acquisition, where a 10 Ct unit increase in

viral load within the household associated with a 65-95% increase in risk depending on

subtype/lineage (A(H1N1)pdm09 hazard ratio (HR), 1.96 95% CI: 1.58-2.44; A(H3N2) 1.64 HR,

95% CI: 1.32-2.03; B/Victoria 1.77 HR, 95% CI: 1.42-2.20; B/Yamagata 1.70 HR, 95% CI: 1.15-

2.52). The community FOI (proxied by influenza infection prevalence in the cohort) was

significantly associated with an increase in risk of infection acquisition for all four

subtypes/lineages, such that a 0.01 increase in community influenza prevalence in the

population, for which the peak prevalence was between 5-6%, was associated with a 70-100%

increase in risk (A(H1N1) pdm09 1.89 HR, 95% CI: 1.68-2.13; A(H3N2) 1.69 HR, 95% CI:

1.56-1.82; B/Victoria 2.01 HR, 95% CI: 1.83-2.20; B/Yamagata 1.95 HR, 95% CI: 1.74-2.19;

supplemental figure 10).

High pre-season HAI titers were protective against infection for all subtypes with the

exception of B/Yamagata, with a titer of at least 1:40 providing a 50-70% reduction in risk of

infection acquisition (Fig 5; A(H1N1) pdm09 0.30 HR, 95% CI: 0.18-0.48; A(H3N2) 0.65 HR,

95% CI: 0.45-0.93; B/Victoria 0.48 HR, 95% CI: 0.31-0.74). Even after controlling for the

household and community FOI as well as pre-season HAI titers, there was still a residual

association between age and risk of infection acquisition. Compared to the reference group of

≥40 years old, children had an increased risk of infection, although the specific age subgroup

exhibiting higher susceptibility depended on the subtype. Those <5 years old had an increased

risk of infection by 170% to 460% for all subtypes except A(H3N2) (A(H1N1)pdm09 2.69 HR,

95% CI: 1.33-5.46; B/Victoria 5.65 HR, 95% CI: 2.85-11.21; B/Yamagata 3.19 HR, 95% CI: 1.33-7.65). Those aged 5-11 years demonstrated a significantly increased risk of infection acquisition compared to the reference group for B/Victoria (B/Victoria 5.66 HR, 95% CI: 2.98-10.73); whereas those in the 12-18 year old group had a higher risk for all subtypes but A(H1N1)pdm09 (A(H3N2) 2.04 HR, 95% CI: 1.19-3.49; B/Victoria 2.17 HR, 95% CI 1.07-4.42; B/Yamagata 3.42 HR, 95% CI 1.61-7.23).

For B/Yamagata infections, larger household size was associated with a decreased risk of infection acquisition, such that one additional person in the household contributed about 10% reduction in risk (0.88 HR, 95% CI 0.80-0.98). For B/Yamagata, compared to individuals that were HIV negative, people living with HIV (PLWH) displayed an increased risk of infection acquisition that scaled with the level of immuno-suppression (PLWH CD4<200 4.07 HR, 95% CI: 1.20-13.86; PLWH CD4>=200 2.65 HR, 95% CI: 1.33-5.28). No other measured characteristic was associated with a significant change in risk of infection acquisition (p-value > 0.05).

Discussion

We analyzed data from the PHIRST cohort in South Africa to refine our understanding of the viral, demographic, and immunologic factors that influence influenza virus transmission. The PHIRST study had a unique design with high frequency real-time reverse transcription polymerase chain reaction (rRT-PCR) sampling at intervals similar to the timescale of influence virus transmission, enabling us to characterize the shedding kinetics of each observed infection episode. In this cohort that comprised a young population with a relatively high prevalence of comorbidities, we demonstrate that age is a stronger predictor of shedding duration than pre-season HAI titers. From the estimated shedding kinetics of household members and viral activity

329   in the cohort, we model the temporal dynamics of influenza exposure within the household and

330   community, both of which are predictive of risk of infection acquisition. Further, we find that

331   pre-season HAI titers are a correlate of protection for the predominant influenza

332   subtypes/lineages (A/H3N2, A/H1N1, B/Victoria); however, even after adjusting for titers,

333   children and adolescents retained higher susceptibility to influenza for all subtypes/lineages.

334   Our results indicate that viral shedding intensity among household contacts was

predictive of the risk of acquiring influenza infection. Specifically, a 10-unit increase in shedding

intensity, as indicated by the Ct value, was associated with approximately a 95% increased risk

for A(H1N1)pdm09, 65% for A(H3N2), 80% for B/Victoria, and 70% for B/Yamagata. This

observed difference between subtypes and lineages may reflect variation in the infectivity of

viral particles, where the same viral load (Ct) corresponds to differing numbers of infectious

virions due to subtype-specific differences in replication efficiency, particle stability, and host

immune responses not fully captured by controlling for HAI titer and age. These findings are

consistent with human challenge studies that have demonstrated a correlation between the risk of

influenza virus infection acquisition and challenge viral dose [1,2]. In contrast, previous case-

ascertained household transmission studies did not observe significant correlations between the

viral shedding intensity of the index case and subsequent infectivity [5,12,18]. These studies

concentrated on post-symptomatic viral shedding and thereby could not evaluate pre-

symptomatic and asymptomatic shedding, as well as exposures to multiple infected household

members. Additionally, the PHIRST cohort included a substantial proportion of children, whose

influenza infection episodes were significantly longer and exhibited higher peak viral loads

compared to adults, after controlling for pre-season HAI titer. The presence of these prolonged

shedding episodes provided the opportunity to examine infectivity hazards with a greater

temporal variability than prior studies, thereby enhancing the statistical power of our analysis.

Similarly, increased prevalence in the general community, estimated from the overall cohort

population, accounting for any exposure outside of the household such as in schools or

workplaces, was also strongly correlated with an increased risk of infection acquisition.

Controlling for time-varying influenza exposures within the household and from the

general community, we found that HAI titers of at least 1:40 were a correlate of protection

against influenza virus infection for all strains except for B/Yamagata, conferring at most 70%

protection against A(H1N1)pdm09 and at least 35% protection against A(H3N2). This

relationship between pre-existing immunity and risk of infection acquisition aligns well with

prior studies that have identified HAI titers of at least 1:40 as providing approximately 50%

reduction in risk, even though this cutoff was based on adults with vaccine-mediated immunity

while the PHIRST cohort was focused on natural immunity [21,22]. Titers against B/Yamagata did

not appear to confer protection when considering a threshold of 1:40. However, running the same

transmission model, with the only difference being to treat titers as a continuous variable rather

than ≥ 40 or <40 categorical, higher B/Yamagata titers did associate with a reduce infection risk

(Supplementary Fig 8). These results suggest either that the threshold for protection may be

higher than 1:40 for this lineage, or that there was a lack of power due to B/Yamagata causing

fewer infections than the other subtypes/lineages in our dataset. Interestingly, the effect size of

A(H3N2) is much smaller than that of A(H1N1)pdm09 and when evaluating the titer on a

continuous basis on a log base four scale, the titer is no longer significantly associated with a

reduction in risk. Putative explanations include antigenic variation in the circulating strain of

A(H3N2) that did not match pre-existing antibody titers, or immune distinctiveness of A(H3N2).

As it relates to age, the observed titer patterns for influenza A indicate a rapid establishment of strain-

specific antibody responses during early childhood, consistent with strong early-life imprinting to

influenza A antigens [27]. In contrast, the broader and less pronounced gradient observed for influenza B

likely reflects less frequent immune boosting due to lower infection rates, as well as the inferior

persistence of antibodies against influenza B viruses compared with influenza A [28,29].

A key result of our study was the strong residual effect of age on the risk of infection

acquisition, after adjustment for HAI titers. Previous research has indicated that children have a

higher risk of infection for both type A and B influenza [14,30]. Compared to older individuals,

children are thought to experience higher contact rates, more exposure-prone behavior, and

relative immunological naivety beyond that measured by HAI titers. Our data can shed light on

the putative contribution of each of these hypotheses. If contact rates and other behavioral risks

were the dominant factors in the age variation in infection risk, there should be consistent age

relationships across all subtypes, as contact rates and behavior universally affect infection

transmission. Kleynhans et al. [31] conducted a cross-sectional study within the PHIRST cohort

and found that children aged 14-18 years had the highest contact rates of all participants. This

could partially explain the heightened risk of infection acquisition observed in individuals aged

12-18 years for A(H3N2), B/Victoria, and B/Yamagata, but it does not support the increased risk

seen in those under 11 years old for A(H1N1)pdm09, B/Victoria, and B/Yamagata. While there

could be other age-specific factors such as contact rates and behavioral heterogeneities

unaccounted for, our data suggests a potential residual effect of age-specific immune responses.

Previous work has suggested that the 1:40 HAI titer cutoff is inaccurate to use as a correlate of

protection when evaluating vaccines for children [23]. While our household model accounts for

variations in pre-existing HAI titers both in categorical and continuous scales, other age-

dependent immune mediators that are not captured by HAI titers likely play a role

(Supplementary Figs 7 and 8). Since children are considered high-transmitters and a key group

for vaccination, it will be important to identify correlates of protection against influenza infection

that are age-appropriate [30,32].

We found a significant gradient of influenza virus shedding duration with age across all

subtypes/lineages in our adjusted models, in which the youngest children shed the longest. We

did not find significant impact of pre-season HAI titer level on shedding duration, except for

influenza A(H1N1)pdm09. Since children, nevertheless, shed the longest, it is possible that

unobserved pre-existing components of adaptive immune memory, such as non-HAI antibodies,

could have reduced the shedding duration. These additional immune functions likely operate on

viral clearance, as the coefficient of variation was significantly higher for clearance duration than

proliferation duration for all but A(H3N2) (Supplementary Table 1). If immune functions beyond

HAI antibodies, such as those targeting neuraminidase, the HA stalk, or other influenza-specific

cellular responses, play a more critical role in promoting viral clearance for A(H3N2),

B/Victoria, and B/Yamagata infections, while pre-existing HAI antibodies are more effective at

preventing infection and correlate more closely with viral control for A(H1N1)pdm09, this could

explain the subtype-specific effects observed on shedding duration [33]. This interpretation aligns

with the hypothesis that pre-season HAI antibodies primarily act to block infection rather than to

reduce viral shedding once infection is established, with the exception of A(H1N1)pdm09, where

HAI titers may better reflect protective immune responses involved in limiting viral replication.

Further, this hypothesis could in part explain why there was no significant association

between titers above 40 and viral load reduction. But it should be noted that there was also no

residual effect of age, and it is also likely that since peak viral load is less directly measurable, it

is likely less accurately estimated and further interpretation is limited. More broadly, the

endemicity of seasonal influenza implies the number of influenza exposures accumulates with

age, and so would immune memory. Overall, immune compartments other than serum HA

antibodies, such as neuraminidase or stalk antibodies, influenza-specific B-cell and T-cell

memory, or binding antibodies that do not inhibit hemagglutination, may contribute to the

prevention of infection acquisition and/or the reduction of viral shedding [2,33–35].

We also explored other individual and household-level characteristics associated with

both the duration of viral shedding and the risk of infection acquisition. Previous studies have

indicated that HIV status influences the risk of morbidity and mortality from influenza-related

illness [36,37]. While there was a relatively large portion of people living with HIV included in our

analysis, most participants living with HIV were on effective treatment, limiting the power of

analysis on immunocompromised individuals. We found no significant correlation between HIV

status, including PLWH who were immunocompromised, and the duration of viral shedding.

However, participants living with HIV had an increased risk of infection acquisition with the

B/Yamagata lineage virus. Additionally, for B/Yamagata, individuals living in larger households

exhibited a lower risk of infection after controlling for household FOI. This finding is consistent

with previous influenza studies that have suggested a "dilution effect" of household contact,

wherein members of larger households experience a reduced per-contact transmission risk

compared with those in smaller households [38]. However, this does not necessarily imply a lower

overall household infection risk, as we observed that the cumulative household infection risk

(defined as the fraction of household members infected during a given season) varied across

households of different sizes (Supplementary Fig 11)."

Our analysis has several limitations. First, despite the extensive rRT-PCR testing scheme,

there were still 2–3-day intervals between sample collections. This could result in missing very

short infection episodes, potentially leading to missed influenza infections. We also did not use

quantitative PCRs but rather used the Ct value as an indirect measure of viral load. Second, our

analysis assumes that pre-season HAI titer measurements remain constant throughout each

influenza season, despite the knowledge that HAI titer might wane over the season. Third, we

were unable to evaluate the impact of co-circulating influenza viruses as we excluded instances

of coinfection from our analysis. Fourth, our transmission model lacks a specific contact

structure, meaning it does not account for heterogeneity in interactions among household

members or demographic differences in community contact exposure [39]. As a result, we cannot

fully resolve the contribution of behavioral and biological risk factors to age differences in

susceptibility, although subtype differences point at possible immunological factors (related to

the amount of antigenic drift and number of past exposures associated with each lineage).

Furthermore, the absence of influenza vaccination in our cohort limits the applicability of our

findings to settings with greater vaccine usage, although it allows us to focus on the role of

natural immunity. Additionally, the number of observed B/Yamagata infections was lower

compared to other subtypes limiting the statistical power for this lineage. It is worth noting that

globally, the B/Yamagata lineage is now considered extinct in the post-COVID-19 pandemic

period [40]. Finally, our study was limited to the pre-COVID-19 period; it remains unclear how the

immunity gap produced by the lack of influenza circulation during the COVID-19 pandemic

would impact the relationship between pre-existing HAI titers, age, and the risk of infection

[10,41,42].

In summary, by modeling high-resolution virological samples from a detailed cohort

study, we were able to reconstruct the time-varying intensities of influenza exposures within

households and from the general community, both of which significantly correlated with the risk

of influenza infection acquisition. After adjusting for these exposures, we found that pre-season

HA antibodies reduced the risk of infection acquisition by influenza A(H1N1)pdm09, A(H3N2),

and B/Victoria, but not B/Yamagata and reduced shedding duration for A(H1N1)pdm09. After

adjustment for HAI titers, we found a residual effect of age on shedding duration and infection

risk. Furthermore, the residual age effects on susceptibility and shedding duration and the

inconsistency of the observed age trend between subtypes highlight the need for more work on

the roles of immune compartments beyond serum HA antibodies, such as antibodies to

neuraminidase and HA stalk, B-cell, T-cell, neutralization and other effector functions of

antibodies as potential correlates of protection against influenza.

Tables/Figures

Table 1. Key characteristics of individuals, households, and influenza viral infections.

			2016	2017	2018
Individual Characteristic	Year		N= 480	N= 523	N= 515
	Site	Agincourt (Rural)	234 (49)	261 (50)	253 (49)
		Klerksdorp (Urban)	246 (51)	262 (50)	262 (51)
	Age Group (years)	<5	59 (12)	58 (11)	59 (11)
		5-11	112 (23)	119 (23)	139 (27)
		12-18	103 (22)	110 (21)	85 (17)
		19-40	115 (24)	102 (19)	142 (28)
		>40	91 (19)	134 (26)	85 (17)
	Sex	Female	286 (60)	309 (59)	325 (63)
		Male	194 (40)	214 (41)	190 (37)
	HIV Status	Negative	403 (84)	440 (84)	400 (78)
		PLWH CD4 ≥200	64 (13)	58 (11)	72 (14)
		PLWH CD4 <200	13 (3)	10 (2)	22 (4)
		Unknown	0	15 (3)	21 (4)
Household Characteristic	Year		2016 N = 100	2017 N = 108 (33)	2018 N = 117
	Household Size	3-5 Members	51 (51)	61 (56)	82 (70)
		6-10 Members	44 (44)	41 (38)	34 (29)
		>10 Members	5 (5)	6 (6)	1 (1)
Observed Infection Episodes	Year		2016 N = 174	2017 N = 239	2018 N = 210
	A(H1N1)pdm09		52 (30)	4 (2)	77 (37)
	A(H3N2)		28 (16)	164 (69)	3 (1)
	B/Victoria		90 (52)	0	130 (62)
	B/Yamagata		4 (2)	71 (30)	0

Key characteristics of individuals and households included in the analysis, and influenza virus infections for which shedding kinetics could be estimated. Brackets indicate percentage relative to the given N for the year and category (Individual Characteristic/ Household Characteristic/ Observed Infection Episodes). See Cohen et al. [7] for all observed individuals and infections.

482   *For the HIV status covariate, PLWH stands for persons living with HIV further defined by*

483   *demonstrating a CD4 T cell count below or equal to and above 200.*

Fig. 1. Distribution of the pre-season serum influenza antibody titers.

Titers shown as a function of age of the participant at enrollment, separated by subtype/lineage.

All participants over 75 are grouped together. The titers were generated using hemagglutination

inhibition assay (HAI) against representative circulating viruses during the study period. The

white solid line is a fitted linear spline fit with B-spline knots at ages 5, 12, 18, and 40 to

describe age-dependent patterns with colored shaded regions representing the 95% confidence

intervals. The black dotted line reflects the standard deviation of the titers across ages.

Fig. 2. Influenza viral shedding kinetics estimates for each subtype/lineage.

(A) Average estimated viral shedding kinetics in Ct values over time since peak shedding (i.e., time since the minimum Ct value). The white solid line represents the posterior mean estimate from the Bayesian piecewise linear viral shedding model, the darker shaded area represents the 95% confidence intervals, and the lighter shaded area represents the interquartile range. (B) Distributions of the proliferation duration estimates for each subtype/lineage. (C-E) same as (B) for clearance duration, total duration, and minimum Ct (peak viral load), respectively.

Fig. 3. Predictors of influenza virus shedding characteristics by subtype/lineage based on multivariable linear regression.

The top panel regresses the total shedding duration and the bottom panel the peak viral load, proxied by the minimum Ct of the infection episode. For the HIV status covariate, PLWH stands for persons living with HIV further defined by demonstrating a CD4 T cell count below or equal to and above 200. For shedding duration, estimates are given in units of days with lines representing the 95% CI. The central line indicates the mean duration for a given

subtype/lineage. The reference groups are designated by a white dot. For the shedding duration

the reference estimates for each subtype are as follows: A(H1N1)pdm09 4.39 days, A(H3N2)

4.71 days, B/Victoria 5.64 days, B/Yamagata 4.94 days. For the minimum Ct of episode, the

reference estimates are A(H1N1)pdm09 22.62 Ct, A(H3N2) 21.06 Ct, B/Victoria 20.54 Ct,

*B/Yamagata 20.72 Ct. Asterisks denote p-value: '***': <0.001 '**': <0.01 '*': <0.05 calculated*

via Satterthwaite's degrees of freedom method.

513 **Fig. 4. Visualization of key variables of the influenza household transmission model.**

514 *Depicts the interplay between community prevalence, household exposure, pre-season titers and*

515 *age. Two individual households, selected from rural (left) and urban (right) communities, are*

516 *presented. Influenza community prevalence (top panel) is shown as a percentage of the enrolled*

517 *cohort with an observed PCR-confirmed infection. The total influenza household exposure*

518 *(second panel) is shown as a composite of individual viral loads Ct values (bottom panel) within*

519 *the household. The ages (in years) and HAI titers of household members are indicated on either*

520 *side. The model is run on a daily time scale.*

Fig. 5. Factors influencing the risk of influenza virus infection acquisition by subtype/lineage based on multivariable logistic regression.

Variables include the community force of infection (FOI), household FOI, pre-season HAI titer, age, sex, HIV status, and household size. Community FOI is indicated with respect to a 0.01 increase in absolute community prevalence (defined as the total number of infection episodes within the cohort at a given time / cohort population). Household FOI is indicated with respect to a step by 10 Ct units within the household. For the HIV status covariate, PLWH stands for persons living with HIV further defined by demonstrating a CD4 T cell count below or equal and above 200. Black dots represent point estimates of hazard ratios (logistic regression is equivalent to a Cox model in this context), with back horizontal lines indicating 95% CI intervals. The

531   *reference groups for categorical variables are designated by a white dot. Asterisks denote p-*

532   *value '***': <0.001 '**': <0.01 '*': <0.05.*

Acknowledgements

The authors would like to thank all the individuals who kindly agreed to participate in the study as well as the PHIRST group. Data collection of the PHIRST flu study was supported by the National Institute for Communicable Diseases of the National Health Laboratory Service (https://www.nicd.ac.za/) and the US Centers for Disease Control and Prevention (https://www.cdc.gov/) (cooperative agreement number 5U51IP000155). MS would like to acknowledge support from Princeton University's Office of Undergraduate Research Undergraduate Fund for Academic Conferences through the President's Fund. BG would like to acknowledge support from Princeton Catalysis and Princeton Precision Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies, the NIH or the U.S. Centers for Disease Control and Prevention.

Author contributions

Conception and design of the study: MS, ST, CV, KS, CC

Data collection and laboratory processing: JK, JM, FkT, OH, AvG, NW, AB, LM, NaM, KK, LL, KM, FW, FxG, ST, CC

Analysis and interpretation: MS, JK, JM, MlM, AvG, NW, ST, BG, CV, KS, CC

Drafting or critical review of the article: MS, JK, JM, MlM, FkT, OH, AvG, NW, AB, LM, NaM, KK, LL, KM, FW, FxG, ST, BG, CV, KS, CC

Competing interests

CC has received grant support from Sanofi Pasteur, US CDC, the Bill & Melinda Gates Foundation, the Taskforce for Global Health, Wellcome Trust and the South African Medical

555 Research Council. AvG has received grant support from Sanofi Pasteur, Pfizer related to
556 pneumococcal vaccine, CDC and the Bill & Melinda Gates Foundation. NW reports grants from
557 Sanofi Pasteur and the Bill & Melinda Gates Foundation. NAM has received a grant to his
558 institution from Pfizer to conduct research in patients with pneumonia and from Roche to collect
559 specimens to assess a novel TB assay.

560 Inclusion & Ethics Statement

The PHIRST protocol was approved by the University of the Witwatersrand Human Research

Ethics Committee (Reference 150808) and the US CDC's Institutional Review Board relied on

the local review (#6840). The protocol was registered on http://clinicaltrials.gov on 6 August

2015 (Reference NCT02519803). Participants provided individual written consent or assent prior

to enrollment and received a grocery store voucher of ZAR25⬜30 (USD 2–2.5) per visit for their

time. (See 45 C.F.R. part 46.114; 21 C.F.R. part 56.114).

567 Data Availability

568 To access data, including individual participant data and a data dictionary defining each field in

569 the dataset, please submit a proposal to C.C. These data can be made available through a data

570 access agreement or material transfer agreement.

571 Code Availability

572 All the statistical analysis for this study and the figures were performed in R (version 4.3.1,

573 RStudio 2023.6.2.561) and the corresponding code with mock data can be found at

574 https://github.com/msauter19/phirst-flu-shed-trans.

575 Supplementary Information

576 Supplementary text, tables, and figures

References

1. Carrat, F. *et al.* Time lines of infection and disease in human influenza: a review of volunteer challenge studies. *Am. J. Epidemiol.* **167**, 775–785 (2008).
2. Memoli, M. J. *et al.* Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **60**, 693–702 (2015).
3. Cohen, C. *et al.* Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017–18 (PHIRST): a population cohort study. *Lancet Glob. Health* **9**, e863–e874 (2021).
4. Ip, D. K. M. *et al.* The Dynamic Relationship Between Clinical Symptomatology and Viral Shedding in Naturally Acquired Seasonal and Pandemic Influenza Virus Infections. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **62**, 431–437 (2016).
5. Lau, L. L. H. *et al.* Viral shedding and clinical illness in naturally acquired influenza virus infections. *J. Infect. Dis.* **201**, 1509–1516 (2010).
6. Tsang, T. K., Lau, L. L. H., Cauchemez, S. & Cowling, B. J. Household Transmission of Influenza Virus. *Trends Microbiol.* **24**, 123–133 (2016).
7. Cohen, C. *et al.* Cohort profile: A Prospective Household cohort study of Influenza, Respiratory syncytial virus and other respiratory pathogens community burden and Transmission dynamics in South Africa, 2016–2018. *Influenza Other Respir. Viruses* **15**, 789–803 (2021).
8. Hayward, A. C. *et al.* Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. *Lancet Respir. Med.* **2**, 445–454 (2014).
9. Horby, P. *et al.* The Epidemiology of Interpandemic and Pandemic Influenza in Vietnam, 2007–2010. *Am. J. Epidemiol.* **175**, 1062–1074 (2012).
10. Rolfes, M. A. *et al.* Household Transmission of Influenza A Viruses in 2021-2022. *JAMA* **329**, 482–489 (2023).
11. Dahlgren, F. S. *et al.* Household transmission of influenza A and B within a prospective cohort during the 2013☐2014 and 2014☐2015 seasons. *Stat. Med.* **40**, 6260–6276 (2021).
12. Ip, D. K. M. *et al.* Viral Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Influenza Virus Infections in the Community. *Clin. Infect. Dis.* **64**, 736–742 (2017).
13. Cohen, C. *et al.* Elevated influenza-related excess mortality in South African elderly individuals, 1998-2005. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **51**, 1362–1369 (2010).
14. Gordon, A. *et al.* Influenza Transmission Dynamics in Urban Households, Managua, Nicaragua, 2012–2014. *Emerg. Infect. Dis.* **24**, (2018).
15. Katz, M. A. *et al.* Influenza in Africa: Uncovering the Epidemiology of a Long-Overlooked Disease. *J. Infect. Dis.* **206**, S1–S4 (2012).
16. Iuliano, A. D. *et al.* Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. *The Lancet* **391**, 1285–1300 (2018).
17. Jernigan, D. B. *et al.* Detecting 2009 pandemic influenza A (H1N1) virus infection: availability of diagnostic testing led to rapid pandemic response. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **52 Suppl 1**, S36-43 (2011).

18. Tsang, T. K. *et al.* Influenza A Virus Shedding and Infectivity in Households. *J. Infect. Dis.* **212**, 1420–1428 (2015).

19. Kissler, S. M. *et al.* Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies. *PLOS Biol.* **19**, e3001333 (2021).

20. Sun, K. *et al.* SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron's impact in South African population cohorts. *Sci. Transl. Med.* **14**, eabo7081 (2022).

21. Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. *J. Hyg. (Lond.)* **70**, 767–777 (1972).

22. Tsang, T. K. *et al.* Association Between Antibody Titers and Protection Against Influenza Virus Infection Within Households. *J. Infect. Dis.* **210**, 684–692 (2014).

23. Black, S. *et al.* Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children. *Pediatr. Infect. Dis. J.* **30**, 1081 (2011).

24. Holford, T. R. The Analysis of Rates and of Survivorship Using Log-Linear Models. *Biometrics* **36**, 299–305 (1980).

25. Laird, N. & Olivier, D. Covariance Analysis of Censored Survival Data Using Log-Linear Analysis Techniques. *J. Am. Stat. Assoc.* **76**, 231–240 (1981).

26. Feltz, C. J. & Miller, G. E. An asymptotic test for the equality of coefficients of variation from k populations. *Stat. Med.* **15**, 646–658 (1996).

27. Yang, B. *et al.* Life course exposures continually shape antibody profiles and risk of seroconversion to influenza. *PLoS Pathog.* **16**, e1008635 (2020).

28. Ranjeva, S. *et al.* Age-specific differences in the dynamics of protective immunity to influenza. *Nat. Commun.* **10**, 1660 (2019).

29. Suntronwong, N. *et al.* Prevalence of antibodies against seasonal influenza A and B viruses among older adults in rural Thailand: A cross-sectional study. *PLOS ONE* **16**, e0256475 (2021).

30. Worby, C. J. *et al.* On the relative role of different age groups in influenza epidemics. *Epidemics* **13**, 10–16 (2015).

31. Kleynhans, J. *et al.* A cross-sectional study measuring contact patterns using diaries in an urban and a rural community in South Africa, 2018. *BMC Public Health* **21**, 1055 (2021).

32. Tsang, T. K. *et al.* Indirect Protection from Vaccinating Children against Influenza A Virus Infection in Households. *Viruses* **14**, 2097 (2022).

33. Hoy, G. *et al.* Anti-Neuraminidase Antibodies Reduce the Susceptibility to and Infectivity of Influenza A/H3N2 Virus. 2024.06.14.24308936 Preprint at https://doi.org/10.1101/2024.06.14.24308936 (2024).

34. Kucharski, A. J. *et al.* Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data. *PLoS Biol.* **13**, e1002082 (2015).

35. Frasca, D. & Blomberg, B. B. Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination. *Immun. Ageing* **17**, 37 (2020).

36. Cohen, C. *et al.* Deaths Associated with Respiratory Syncytial and Influenza Viruses among Persons ≥5 Years of Age in HIV-Prevalent Area, South Africa, 1998–2009. *Emerg. Infect. Dis.* **21**, 600–608 (2015).

37. Gessner, B. D., Shindo, N. & Briand, S. Seasonal influenza epidemiology in sub-Saharan Africa: a systematic review. *Lancet Infect. Dis.* **11**, 223–235 (2011).

38. Cauchemez, S. *et al.* Determinants of Influenza Transmission in South East Asia: Insights from a Household Cohort Study in Vietnam. *PLoS Pathog.* **10**, e1004310 (2014).

39. Sun, K. *et al.* Behavioral factors and SARS-CoV-2 transmission heterogeneity within a household cohort in Costa Rica. *Commun. Med.* **3**, 1–8 (2023).

40. Marchi, S. *et al.* Prevalence of Influenza B/Yamagata Viruses From Season 2012/2013 to 2021/2022 in Italy as an Indication of a Potential Lineage Extinction. *Influenza Other Respir. Viruses* **18**, e13359 (2024).

41. Ali, S. T. *et al.* Prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic: a modelling study. *Lancet Glob. Health* **10**, e1612–e1622 (2022).

42. Lee, S. S., Viboud, C. & Petersen, E. Understanding the rebound of influenza in the post COVID-19 pandemic period holds important clues for epidemiology and control. *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis.* **122**, 1002–1004 (2022).